Sinotherapeutics Inc. A Market Cap ($529.38 Million)
Market Cap & Net Worth: Sinotherapeutics Inc. A (688247)
Sinotherapeutics Inc. A market cap. Sinotherapeutics Inc. A (SHG:688247) has a market capitalization of $529.38 Million (CN¥3.62 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #11577 globally and #3277 in its home market, demonstrating a -0.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sinotherapeutics Inc. A's stock price CN¥7.98 by its total outstanding shares 453340000 (453.34 Million). Also see 688247 operating cash flow for how efficiently the company converts equity into cash flow.
Sinotherapeutics Inc. A Market Cap History (2022–2026)
Sinotherapeutics Inc. A market cap history from 2022 to 2026. Data shows change from $1.10 Billion to $529.38 Million (-11.65% CAGR). Check 688247 live share price for real-time trading data and today's change.
Sinotherapeutics Inc. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sinotherapeutics Inc. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Sinotherapeutics Inc. A annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.44x
Sinotherapeutics Inc. A's market cap is 1.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
13.55x
Sinotherapeutics Inc. A's market cap is 13.55 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.10 Billion | $247.56 Million | $92.93 Million | 4.43x | 11.81x |
| 2023 | $722.93 Million | $299.87 Million | $61.07 Million | 2.41x | 11.84x |
| 2024 | $667.36 Million | $511.62 Million | $127.70 Million | 1.30x | 5.23x |
| 2025 | $643.48 Million | $446.57 Million | $47.48 Million | 1.44x | 13.55x |
Competitor Companies of 688247 by Market Capitalization
Companies near Sinotherapeutics Inc. A in the global market cap rankings as of November 8, 2026. Also see 688247 total assets for a full breakdown of the balance sheet.
Key companies related to Sinotherapeutics Inc. A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Sinotherapeutics Inc. A (2022–2026)
Market capitalization of Sinotherapeutics Inc. A from 2022 to today. Between 2022 and today, Sinotherapeutics Inc. A's market cap moved from $1.10 Billion to $ 529.38 Million, with a yearly change of -11.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥529.38 Million | -17.73% |
| 2025 | CN¥643.48 Million | -3.58% |
| 2024 | CN¥667.36 Million | -7.69% |
| 2023 | CN¥722.93 Million | -34.12% |
| 2022 | CN¥1.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Sinotherapeutics Inc. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $529.38 Million USD |
| MoneyControl | $529.38 Million USD |
| MarketWatch | $529.38 Million USD |
| marketcap.company | $529.38 Million USD |
| Reuters | $529.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sinotherapeutics Inc. A
Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extende… Read more